<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339089</url>
  </required_header>
  <id_info>
    <org_study_id>P16-828</org_study_id>
    <nct_id>NCT03339089</nct_id>
  </id_info>
  <brief_title>Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases</brief_title>
  <acronym>ADMIT</acronym>
  <official_title>Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of adalimumab on health outcomes in
      participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in EuroQoL-5 Dimension (EQ-5D) index score up to Week 24</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>The European quality of life-5 dimensions (EQ-5D) is a simple, easy to administer, standardized and self-report instrument for health status, which is applicable to a wide range of health conditions and treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing drug persistence</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is measured using drug survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Healthcare Resource Utilization (HCRU)</measure>
    <time_frame>From Week 0 to Week 52</time_frame>
    <description>This is assessed using the HCRU questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Work productivity and Activity Impairment questionnaire - Specific Health Problem (WPAI-SHP) in participants with Ankylosing spondylitis (AS)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>WPAI questionnaire will be used to measure work absenteeism, work presenteeism, and daily activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI) in participants with Psoriasis (Ps)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is the most commonly used quality of life (QoL) assessment tool in psoriasis clinical research.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Work productivity and Activity Impairment questionnaire - Specific Health Problem (WPAI-SHP) in participants with Rheumatoid Arthritis (RA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>WPAI questionnaire will be used to measure work absenteeism, work presenteeism, and daily activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Disease Activity Index (CDAI) in participants with Rheumatoid Arthritis (RA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The CDAI is used to evaluate disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving low disease activity (CDAI 2.8-10) in participants with Rheumatoid Arthritis (RA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The CDAI is used to evaluate disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in participants with Ankylosing spondylitis (AS)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>BASDAI score is determined using a simple, self-reported questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving remission (CDAI&lt;=2.8) in participants with Rheumatoid Arthritis (RA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The CDAI is used to evaluate disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-5D Visual analog scale (VAS)</measure>
    <time_frame>From Week 0 to Week 52</time_frame>
    <description>It is a patient-reported outcome (PRO) questionnaires used to assess quality of life (QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-5D index score up to Week 52</measure>
    <time_frame>From Week 0 to Week 52</time_frame>
    <description>The European quality of life-5 dimensions (EQ-5D) is a simple, easy to administer, standardized and self-report instrument for health status, which is applicable to a wide range of health conditions and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response in participants with Ankylosing spondylitis (AS)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>BASDAI score is determined using a simple, self-reported questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Psoriasis Area and Severity Index (PASI) in participants with Psoriasis (Ps)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>PASI provides a quantitative assessment of psoriasis disease state.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ankylosing Spondylitis (AS)</condition>
  <condition>Psoriasis</condition>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Participants with Rheumatoid Arthritis (RA)</arm_group_label>
    <description>This group/ cohort includes participants with RA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Plaque Psoriasis (Ps)</arm_group_label>
    <description>This group/ cohort includes participants with Ps.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Ankylosing spondylitis (AS)</arm_group_label>
    <description>This group/ cohort includes participants with AS.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese participants diagnosed with rheumatoid arthritis, ankylosing spondylitis or plaque
        psoriasis, for whom adalimumab (Humira®) treatment has already been decided as per local
        label, will be recruited from within the clinical setting of each rheumatologist or
        dermatologist participating in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or
             plaque psoriasis

          -  Decision to initiate Humira® treatment in accordance with routine medical practice and
             in compliance with eligibility for adalimumab based on the local label

          -  Prior to any study-specific procedures, participant has voluntarily signed the
             authorization (or informed consent where applicable) to disclose and use anonymized
             personal health information after participate in this research.

        Exclusion Criteria:

          -  Inadequate response to previous standard treatment with anti-tumor necrosis factor
             (TNF) biological agent according to the physician's clinical judgment.

          -  Participant has been treated with adalimumab within 70 days (five half-lives) prior to
             the Baseline Visit.

          -  Participants discontinued due to adverse drug reaction of previous adalimumab
             treatment.

          -  Participants who fulfill any of the contraindications as per adalimumab label in
             China.

          -  Participants, who in the clinician's view, may not be able to comply with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nian Liang</last_name>
    <phone>+86 21 62631487</phone>
    <email>nian.liang@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AbbVie China</name>
      <address>
        <city>Shanghai</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>plaque psoriasis</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>Immune-Mediated Inflammatory Diseases</keyword>
  <keyword>Chinese Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

